Belite Bio (BLTE) reported a Q1 adjusted loss Wednesday of $0.34 per diluted share, widening from a loss of $0.24 a year earlier.
One analyst surveyed by FactSet expected a loss of $0.69.
The company had cash, cash equivalents, and US treasury bills and notes of $798.6 million as of March 31.